juvenal (![[info]](http://klab.lv/img/userinfo.gif){kind=small} juvenal) rakstīja,@ 2025-03-15 03:35:00 |
 |
 |
 |
|
|
|
|
|
|
 |
|
 |
Ir cerīgi klīniskie testi un pētījumi par pretsvara zālēm, kas saglabā vai pat audzē muskuļu masu https://www.reuters.com/business/healthcare-pharmaceuticals/next-generation-weight-loss-drugs-aim-save-muscle-2025-02-19
Tie ir ļoti vajadzīgi, jo esošie semaglutīdi, slavenās Wegivy un Ozempic 40% no nomestā svara panāk ar muskuļu iznīcināšanu. Tas, protams, ir absurds.
Bet ASV FDA nostāja
"Analysts and clinical trial experts expressed doubts on whether FDA would approve a drug solely on muscle-mass effect.
"There's a real uphill battle to get something like that approved because the FDA does not approve drugs on the basis of muscle building or muscle preservation in this (obesity) setting," said BMO Capital Markets analyst Evan Seigerman."
Reāli iespārda.
Trampu un Kenediju, lūdzu!
Tie ir ļoti vajadzīgi, jo esošie semaglutīdi, slavenās Wegivy un Ozempic 40% no nomestā svara panāk ar muskuļu iznīcināšanu. Tas, protams, ir absurds.
Bet ASV FDA nostāja
"Analysts and clinical trial experts expressed doubts on whether FDA would approve a drug solely on muscle-mass effect.
"There's a real uphill battle to get something like that approved because the FDA does not approve drugs on the basis of muscle building or muscle preservation in this (obesity) setting," said BMO Capital Markets analyst Evan Seigerman."
Reāli iespārda.
Trampu un Kenediju, lūdzu!
Nopūsties:
